Platinum-Resistant Ovarian CancerPhase 1NCT06964009
DT2216
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
What the film says
Ovarian cancer usually answers to platinum chemotherapy at first. When it stops answering, the remaining drugs buy months, and most disease sits inside the abdomen, where it seeds the lining and causes fluid to build.
The idea: put trained natural killer cells exactly there.
At Dana-Farber, a patient's own natural killer cells are collected, then exposed overnight to three immune signals, interleukins 12, 15, and 18, which leaves them in a memory-like state: more alert, longer-lived. After chemotherapy makes room, the cells are infused directly into the abdominal cavity, followed by low doses of interleukin-2 under the skin to keep them active.
An early safety study for recurrent, platinum-resistant high-grade ovarian cancer. Rebecca Porter leads it in Boston. Public record; not medical advice.
Sources behind this film
Platinum-resistant recurrence; limited options; peritoneal spread; Autologous NK cells via leukapheresis; CIML = IL-12/15/18 pre-activation; Lymphodepleting chemotherapy days −6 to −2; intraperitoneal infusion day 0; SC low-dose IL-2 day 0 and every other day ×4 (+1 more lines)
The drug
Cytokine Induced Memory-like Natural Killer (CIML NK) Cells Autologous, cytokine induced memory-like natural killer cells, via intraperitoneal (IP) infusion per protocol.
Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
This is an open-label, single site, phase 1b study to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer. Participants will be enrolled to test the safety of intraperitoneal CIML NK cell therapy The U.S. Food and Drug Administration (FDA) has not approved CIML NK cell therapy as a treatment for recurrent, high grade ovarian cancer.
The study
The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.